SHERIDAN, WYOMING – August 8, 2025 – Major pharmaceutical companies are doubling down on venture funds and incubator programs to identify cutting-edge science, foster strategic partnerships, and position themselves in emerging therapeutic and geographic markets. While mergers and acquisitions remain a dominant growth driver, these initiatives provide a long-term “farm system” for high-value pipeline assets.
From Discovery Hubs to Strategic Pipelines
Eli Lilly’s Lilly Gateway Labs and Boehringer Ingelheim’s Venture Fund illustrate how Big Pharma is building innovation capacity beyond their core research programs. These initiatives target startups with disruptive science in neuroscience, oncology, immunology, and cardiometabolic health—while also venturing into high-risk areas such as neurodegenerative diseases and healthspan research.
Boehringer’s portfolio, for example, includes more than 40 companies in autoimmunity, regenerative medicine, and digital health. “The front runner project in this company needs to stand on their own legs, must be the value driver, because we do not want to entertain a clinical trial with venture money [if it] has no commercial value,” said Detlev Mennerich, global head of the Boehringer Ingelheim Venture Fund.
Expanding Therapeutic and Geographic Reach
Many investments are deliberately outside existing pipelines to anticipate future market needs. Boehringer’s focus on novel ALS targets through Rgenta Therapeutics and Libra Therapeutics reflects a willingness to “enter that space” through early-stage bets. Lilly, meanwhile, is exploring adjacent fields such as longevity, assessing their potential relevance across existing therapeutic franchises.
Geographic strategy also plays a role. Roche’s Accelerator, launched in 2021, is designed to embed the company in China’s fast-growing biotech ecosystem. Nearly 20 local startups have been selected from over 500 applicants, working on technologies from molecular glues to AI-driven drug discovery.
Capital, Capabilities, and Co-Creation
While models differ, most programs combine funding with industry expertise:
- Pfizer Ventures: $900 million committed to early-stage opportunities, plus scientific advisory participation
- Novartis Venture Fund: ~$750 million under management, active board involvement in portfolio companies
- Lilly Gateway Labs: Hands-on incubator support for up to four years, leveraging Lilly’s R&D and regulatory expertise
This hybrid approach offers startups both capital and operational guidance, while giving pharma sponsors early visibility into promising science.
Industry Trends Driving the Incubator Surge
The rise of incubators and venture arms reflects several converging trends:
- External innovation dependence – Nearly half of large pharma pipelines are sourced externally
- Rising R&D costs – Early de-risking of assets before full integration
- Global science hotspots – Targeted expansion into emerging biotech markets
- Therapeutic diversification – Entry into adjacent or high-risk disease areas ahead of competitors
Positioning for the Next Decade
For pharma companies, these programs are more than corporate social responsibility—they are strategic levers to secure competitive advantage. By nurturing startups that may one day become acquisition targets or long-term partners, Big Pharma builds optionality into its future portfolio.
For the startups, the payoff is access to industry-scale expertise, regulatory insight, and the potential for commercialization pathways that might otherwise take years to develop.
As therapeutic landscapes evolve, these venture and incubator ecosystems are poised to shape not just company pipelines but the next decade of drug development strategy.
Learn more at www.fairsonline.org